Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3020
Gene Symbol: H3-3A
H3-3A
0.400 GeneticVariation disease BEFREE No significant prognostic value was observed for grade, even after regrading H3F3A K27M-mutated midline glioma as grade IV (WHO 2016). 31419298 2020
Entrez Id: 3020
Gene Symbol: H3-3A
H3-3A
0.400 GeneticVariation disease BEFREE H3 K27 mutations, most commonly in H3F3A, are common in diffuse midline glioma. 30864101 2019
Entrez Id: 3020
Gene Symbol: H3-3A
H3-3A
0.400 GeneticVariation disease BEFREE The case emphasizes the importance of comprehensive assessment based on pathological, genetic and clinical findings and calls for further investigations of non-diffuse glioma with H3F3A K27M and glioma with H3F3A K27M and BRAF V600E. 31254135 2019
Entrez Id: 3020
Gene Symbol: H3-3A
H3-3A
0.400 GeneticVariation disease BEFREE Previous data suggest that expression of transcription factors FoxG1 and Olig-2 can separate hotspot histone H3 family member 3A (H3F3A)-mutant tumours in paediatric glioma. 29053887 2018
Entrez Id: 3020
Gene Symbol: H3-3A
H3-3A
0.400 GeneticVariation disease BEFREE Frequent mutations in chromatin-modifier genes were identified including, noticeably, a truncating mutation in SETD2 (n = 4), which resulted in loss of H3K36 trimethylation and was mutually exclusive with H3F3A K27M mutation (n = 3), suggesting that epigenetic dysregulation may lead to DCG tumorigenesis. 28852847 2017
Entrez Id: 3020
Gene Symbol: H3-3A
H3-3A
0.400 GeneticVariation disease BEFREE Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR. 26376656 2016
Entrez Id: 3020
Gene Symbol: H3-3A
H3-3A
0.400 GeneticVariation disease BEFREE Diffuse gliomas with ATRX loss (n = 137, median 1413 days, 95 % CI: 1065-1860 days) revealed a significantly better clinical outcome compared with tumors with ATRX retention (n = 335, median: 609, 95 % CI: 539-760 days, HR = 1.81, p < 0.0001).In conclusion, ATRX is a potential marker for prediction of IDH/H3F3A mutations and substratification of diffuse gliomas into survival relevant tumor groups. 27311324 2016
Entrez Id: 3020
Gene Symbol: H3-3A
H3-3A
0.400 GeneticVariation disease BEFREE CDKN2A, and PTEN in high-grade gliomas, followed by BRAF fusions in low-grade gliomas and H3F3A mutations in pediatric gliomas. 26681766 2016
Entrez Id: 3020
Gene Symbol: H3-3A
H3-3A
0.400 GeneticVariation disease BEFREE We report a case of thalamic glioma with H3F3A K27M mutation, which was detected in both the primary tumor diagnosed as diffuse astrocytoma obtained during the first surgery and also in the tumor diagnosed as anaplastic astrocytoma obtained at the second surgery. 27392443 2016
Entrez Id: 3020
Gene Symbol: H3-3A
H3-3A
0.400 GeneticVariation disease BEFREE Here, we sought to determine the association between H3F3A mutations and adult thalamic glioma. 24285547 2014
Entrez Id: 3020
Gene Symbol: H3-3A
H3-3A
0.400 Biomarker disease BEFREE We performed gene mutation analysis of IDH1 and H3 histone family 3A (H3F3A), status evaluation of glioma cytosine-phosphate-guanine island methylator phenotype (G-CIMP), and Gene Ontology analysis. 24997139 2014
Entrez Id: 3020
Gene Symbol: H3-3A
H3-3A
0.400 Biomarker disease CTD_human Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. 23583981 2013
Entrez Id: 3020
Gene Symbol: H3-3A
H3-3A
0.400 Biomarker disease BEFREE Prevalences of mutations of isocitrate dehydrogenase 1 (IDH1) and histone H3.3 (H3F3A), the glioma cytosine-phosphate-guanine island methylator phenotype (G-CIMP), and methylation of alkylpurine DNA N-glycosylase (APNG) and peroxiredoxin 1 (PRDX1) promoters were determined in a representative biomarker subset (n = 126 patients with anaplastic astrocytoma or glioblastoma) from the NOA-08 trial. 23595628 2013
Entrez Id: 3020
Gene Symbol: H3-3A
H3-3A
0.400 Biomarker disease CTD_human Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. 22286216 2012